AIMS: To determine fasting and postprandial metabolism of apolipoprotein B48 (apoB48) remnant lipoproteins in subjects with Type 1 diabetes and the relationship to progressive cardiovascular disease, and to investigate the impact of remnant lipoprotein cholesterol accumulation associated with arterial wall biglycan using a rodent model of Type 1 diabetes. METHODS: Normolipidaemic subjects (n = 9) with long-standing Type 1 diabetes (and advanced cardiovascular disease) and seven healthy control subjects were studied. Fasting and postprandial apoB48 concentration was determined following a sequential meal challenge. A rodent model of streptozotocin-induced diabetes was used to investigate the ex vivo retention of fluorescent-conjugated remnants. Binding of remnant lipoproteins to human recombinant biglycan was assessed in vitro. RESULTS: A significantly higher concentration of fasting plasma apoB48 remnants was observed in patients with Type 1 diabetes compared with control subjects. Patients with Type 1 diabetes exhibited a greater total plasma apoB48 area under the curve (AUC) and an increased incremental AUC following a second sequential meal compared with control subjects. The arterial retention of remnants ex vivo and associated cholesterol was increased sevenfold in Type 1 diabetes rats relative to controls. Remnants were shown to bind with significant affinity to human biglycan in vitro and a further 2.3-fold increased binding capacity was observed with glycated biglycan. Remnants were shown to colocalize with both arterial biglycan and glycated matrix proteins in the Type 1 diabetes rodent model. CONCLUSION: Impaired metabolism of remnant lipoproteins associated with enhanced binding to proteoglycans appears to contribute to the arterial cholesterol deposition in Type 1 diabetes. Our findings support the hypothesis that impaired remnant metabolism may contribute to accelerated progression of atherosclerosis in the hyperglycaemic and insulin-deficient state.
AIMS: To determine fasting and postprandial metabolism of apolipoprotein B48 (apoB48) remnant lipoproteins in subjects with Type 1 diabetes and the relationship to progressive cardiovascular disease, and to investigate the impact of remnant lipoprotein cholesterol accumulation associated with arterial wall biglycan using a rodent model of Type 1 diabetes. METHODS: Normolipidaemic subjects (n = 9) with long-standing Type 1 diabetes (and advanced cardiovascular disease) and seven healthy control subjects were studied. Fasting and postprandial apoB48 concentration was determined following a sequential meal challenge. A rodent model of streptozotocin-induced diabetes was used to investigate the ex vivo retention of fluorescent-conjugated remnants. Binding of remnant lipoproteins to human recombinant biglycan was assessed in vitro. RESULTS: A significantly higher concentration of fasting plasma apoB48 remnants was observed in patients with Type 1 diabetes compared with control subjects. Patients with Type 1 diabetes exhibited a greater total plasma apoB48 area under the curve (AUC) and an increased incremental AUC following a second sequential meal compared with control subjects. The arterial retention of remnants ex vivo and associated cholesterol was increased sevenfold in Type 1 diabetesrats relative to controls. Remnants were shown to bind with significant affinity to humanbiglycan in vitro and a further 2.3-fold increased binding capacity was observed with glycated biglycan. Remnants were shown to colocalize with both arterial biglycan and glycated matrix proteins in the Type 1 diabetes rodent model. CONCLUSION: Impaired metabolism of remnant lipoproteins associated with enhanced binding to proteoglycans appears to contribute to the arterial cholesterol deposition in Type 1 diabetes. Our findings support the hypothesis that impaired remnant metabolism may contribute to accelerated progression of atherosclerosis in the hyperglycaemic and insulin-deficient state.
Authors: Teresa Buckner; Baohai Shao; Robert H Eckel; Jay W Heinecke; Karin E Bornfeldt; Janet Snell-Bergeon Journal: J Clin Lipidol Date: 2020-10-31 Impact factor: 5.365
Authors: Mariann I Lassenius; Ville-Petteri Mäkinen; Christopher L Fogarty; Lina Peräneva; Matti Jauhiainen; Pirkko J Pussinen; Marja-Riitta Taskinen; Juha Kirveskari; Outi Vaarala; Janne K Nieminen; Sohvi Hörkkö; Antti J Kangas; Pasi Soininen; Mika Ala-Korpela; Daniel Gordin; Aila J Ahola; Carol Forsblom; Per-Henrik Groop; Markku Lehto Journal: Nutr Metab (Lond) Date: 2014-06-13 Impact factor: 4.169
Authors: Abdoulaye Diane; W David Pierce; Sandra E Kelly; Sharon Sokolik; Faye Borthwick; Miriam Jacome-Sosa; Rabban Mangat; Jesus Miguel Pradillo; Stuart McRae Allan; Megan R Ruth; Catherine J Field; Rebecca Hutcheson; Petra Rocic; James C Russell; Donna F Vine; Spencer D Proctor Journal: Front Nutr Date: 2016-10-10
Authors: Rabban Mangat; Samantha Warnakula; Faye Borthwick; Zahra Hassanali; Richard R E Uwiera; James C Russell; Christopher I Cheeseman; Donna F Vine; Spencer D Proctor Journal: J Am Heart Assoc Date: 2012-10-25 Impact factor: 5.501